215 related articles for article (PubMed ID: 25592409)
1. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.
Kubica A; Kasprzak M; Obońska K; Fabiszak T; Laskowska E; Navarese EP; Koziński M; Sztuba B; Świątkiewicz I; Grześk G; Kubica J
Pharmacology; 2015; 95(1-2):50-8. PubMed ID: 25592409
[TBL] [Abstract][Full Text] [Related]
2. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction.
Kubica A; Kasprzak M; Siller-Matula J; Koziński M; Pio Navarese E; Obońska K; Andruszkiewicz A; Sztuba B; Fabiszak T; Swiątkiewicz I; Paciorek P; Kubica J
Eur J Pharmacol; 2014 Nov; 742():47-54. PubMed ID: 25199965
[TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
5. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
[TBL] [Abstract][Full Text] [Related]
6. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Matetzky S; Shenkman B; Guetta V; Shechter M; Beinart R; Goldenberg I; Novikov I; Pres H; Savion N; Varon D; Hod H
Circulation; 2004 Jun; 109(25):3171-5. PubMed ID: 15184279
[TBL] [Abstract][Full Text] [Related]
8. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
[TBL] [Abstract][Full Text] [Related]
11. Prediction of high risk of non-adherence to antiplatelet treatment.
Kubica A; Obońska K; Kasprzak M; Sztuba B; Navarese EP; Koziński M; Świątkiewicz I; Kieszkowska M; Ostrowska M; Grześk G; Kubica J
Kardiol Pol; 2016; 74(1):61-7. PubMed ID: 26101025
[TBL] [Abstract][Full Text] [Related]
12. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
[TBL] [Abstract][Full Text] [Related]
14. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
15. Impact of initial clinical presentation on clopidogrel low response.
Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Guimarães PO; Tricoci P
Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
20. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
